M2011
Melphalan
powder
Synonym(s):
4-[Bis(2-chloroethyl)amino]-L-phenylalanine, L-PAM, L-Phenylalanine mustard
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C13H18Cl2N2O2
CAS Number:
Molecular Weight:
305.20
UNSPSC Code:
12352207
NACRES:
NA.32
PubChem Substance ID:
EC Number:
205-726-3
Beilstein/REAXYS Number:
2816456
MDL number:
Form:
powder
form
powder
Quality Level
color
white
SMILES string
N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O
InChI
1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
InChI key
SGDBTWWWUNNDEQ-LBPRGKRZSA-N
General description
Melphalan also known as L-phenylalanine mustard is an alkylating agent. It belongs to the class of nitrogen mustards, which act as chemotherapeutic agents.
Application
Melphalan has been used as a drug along with HDAC-inhibitor JNJ-26481585 to treat multiple myeloma (MM) in cell lines and as a chemotherapeutic agent for breast cancer cell line.
Biochem/physiol Actions
Melphalan is an antineoplastic agent.
In rat, melphalan in isolated lung perfusion (ILP) functions as a potent therapeutics for sarcomatous pulmonary metastases. It forms DNA intrastrand crosslinks by bifunctional alkylation in 5′-GGC sequences. Melphalan acts as a bone-marrow depressant and is implicated in the treatment of multiple myeloma and ovarian cancer.
Still not finding the right product?
Explore all of our products under Melphalan
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1A - Muta. 1B - Repr. 2 - Skin Sens. 1
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
Stuhmer T
British Journal of Haematology, 149(4), 529-536 (2010)
G B Bauer et al.
Nucleic acids research, 25(6), 1211-1218 (1997-03-15)
Previous work showed that melphalan-induced mutations in the aprt gene of CHO cells are primarily transversions and occur preferentially at G-G-C sequences, which are potential sites for various bifunctional alkylations involving guanine N-7. To identify the DNA lesion(s) which may
Niels Wcj van de Donk et al.
The Lancet. Haematology, 5(10), e479-e492 (2018-10-07)
In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of